PBA
BLTE

Paradigm Biocapital Advisors’s Belite Bio BLTE Stock Holding History

Paradigm Biocapital Advisors’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$190M Buy
1,232,877
+118,093
+11% +$18.1M 3.55% 9
2026
Q1 		$178M Buy
+1,114,784
New +$187M 3.63% 9

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Paradigm Biocapital Advisors's BLTE Position: Q2 2026 in Review

Paradigm Biocapital Advisors increased its Belite Bio (BLTE) stake by 11% in Q2 2026, buying an estimated $18.1M and bringing the position to 1,232,877 shares worth $190M. The position accounts for 3.55% of the portfolio, ranked #9.

Paradigm Biocapital Advisors first reported a position in BLTE in Q1 2026 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • Paradigm Biocapital Advisors held 1,232,877 shares of Belite Bio worth $190M as of Q2 2026.
  • Paradigm Biocapital Advisors bought 118,093 Belite Bio shares in Q2 2026, an estimated $18.1M.
  • Belite Bio made up 3.55% of Paradigm Biocapital Advisors's portfolio in Q2 2026, its #9 holding.
  • Paradigm Biocapital Advisors first reported a position in Belite Bio in Q1 2026 and has held it in 2 quarters since.
  • 81 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.